文献速递肿瘤 PET/CT核素与放射性配体治疗

生理性结肠[18F]FDG摄取在PET/CT成像中能否预测转移性黑色素瘤免疫治疗反应

Can physiologic colonic [18F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-07-15

本研究纳入119例计划接受伊匹木单抗单药或联合纳武利尤单抗治疗的IV期黑色素瘤患者,于免疫检查点抑制剂(ICI)开始前行基线[18F]FDG PET/CT,分析结肠、脾脏及骨髓的摄取参数与临床结局的关系。结果显示结肠SUV及结肠-肝脏比值(CLR)与生存无独立预测关系,但结肠MTV、TLG及脾脏、骨髓的SUV比值与疾病控制及生存相关。

要点

  • 结肠SUV及CLR与PFS、OS仅呈延长趋势,未达统计学显著。
  • 疾病控制组(SD/PR/CR)的结肠MTV、TLG显著低于进展组(PD)。
  • 多因素分析中,结肠MTV和TLG与PFS显著负相关,BLRmax与PFS和OS显著负相关。

核心结论

  • 基于伊匹木单抗治疗前,PET/CT所测生理性结肠[18F]FDG摄取(以SUV评估)似乎不能独立预测转移性黑色素瘤患者的生存。
  • 源自正常肠道的体积PET参数(如MTV和TLG)可识别对免疫治疗达疾病控制的患者,并与PFS显著相关。
  • 脾脏和骨髓的葡萄糖代谢检查可能提供预后信息。

研究设计与样本

  • 研究纳入119例计划接受伊匹木单抗单药或联合纳武利尤单抗治疗的IV期黑色素瘤患者,于基线行[18F]FDG PET/CT。
  • PET/CT分析包括结肠的SUV、MTV、TLG计算以及结肠-肝脏SUV比值(CLRmean、CLRmax)测量,并基于四点量表对结肠摄取进行视觉分级。
  • 同时计算脾脏-肝脏SUV比值(SLRmean、SLRmax)和骨髓-肝脏SUV比值(BLRmean、BLRmax),并测量血清脂多糖(LPS)水平作为细菌易位标志物和黏膜防御稳态的替代指标。
  • 结果与患者最佳临床反应、无进展生存期(PFS)、总生存期(OS)以及结肠炎的临床体征进行相关性分析。

主要发现

  • 自免疫治疗开始的中位随访时间为64.6个月(95%CI 61.0-68.6个月)。
  • 最佳治疗反应为进展性疾病(PD)者60例,疾病稳定(SD)者37例,部分缓解(PR)者18例,完全缓解(CR)者4例。
  • Kaplan-Meier曲线显示,结肠SUV和CLR值较低的患者有更长PFS和OS的趋势,但这些参数作为预后因素未达统计学显著。
  • 最佳反应为疾病控制(SD、PR、CR)的患者,其结肠MTV和TLG显著低于最佳反应为PD的患者;疾病控制患者的基线SLRmax和BLRmax也显著低于进展患者。
  • SLRmax和BLRmax值较低(以中位数二分)的患者OS显著更长;多因素分析中,与患者生存显著负相关的PET参数为结肠MTV(PFS)、结肠TLG(PFS)以及BLRmax(PFS和OS)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The development of biomarkers that can reliably and early predict response to immune checkpoint inhibitors (ICIs) is crucial in melanoma. In recent years, the gut microbiome has emerged as an important regulator of immunotherapy response, which may, moreover, serve as a surrogate marker and prognosticator in oncological patients under immunotherapy. Aim of the present study is to investigate if physiologic colonic [18F]FDG uptake in PET/CT before start of ICIs correlates with clinical outcome of metastatic melanoma patients. The relation between [18F]FDG uptake in lymphoid cell-rich organs and long-term patient outcome is also assessed. METHODOLOGY: One hundred nineteen stage IV melanoma patients scheduled for immunotherapy with ipilimumab, applied either as monotherapy or in combination with nivolumab, underwent baseline [18F]FDG PET/CT. PET/CT data analysis consisted of standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) calculations in the colon as well as measurements of the colon-to-liver SUV ratios (CLRmean, CLRmax). Visual grading of colon uptake based on a four-point scale was also performed. Moreover, the spleen-to-liver SUV ratios (SLRmean, SLRmax) and the bone marrow-to-liver SUV ratios (BLRmean, BLRmax) were calculated. We also measured serum lipopolysaccharide (LPS) levels as a marker for bacterial translocation and surrogate for mucosal defense homeostasis. The results were correlated with patients' best clinical response, progression-free survival (PFS), and overall survival (OS) as well as clinical signs of colitis. RESULTS: Median follow-up [95%CI] from the beginning of immunotherapy was 64.6 months [61.0-68.6 months]. Best response to treatment was progressive disease (PD) for 60 patients, stable disease (SD) for 37 patients, partial response (PR) for 18 patients, and complete response (CR) for 4 patients. Kaplan-Meier curves demonstrated a trend for longer PFS and OS in patients with lower colonic SUV and CLR values; however, no statistical significance for these parameters as prognostic factors was demonstrated. On the other hand, patients showing disease control as best response to treatment (SD, PR, CR) had significantly lower colonic MTV and TLG than those showing PD. With regard to lymphoid cell-rich organs, significantly lower baseline SLRmax and BLRmax were observed in patients responding with disease control than progression to treatment. Furthermore, patients with lower SLRmax and BLRmax values had a significantly longer OS when dichotomized at their median. In multivariate analysis, PET parameters that were found to significantly adversely correlate with patient survival were colonic MTV for PFS, colonic TLG for PFS, and BLRmax for PFS and OS. CONCLUSIONS: Physiologic colonic [18F]FDG uptake in PET/CT, as assessed by means of SUV, before start of ipilimumab-based treatment does not seem to independently predict patient survival of metastatic melanoma. On the other hand, volumetric PET parameters, such as MTV and TLG, derived from the normal gut may identify patients showing disease control to immunotherapy and significantly correlate with PFS. Moreover, the investigation of glucose metabolism in the spleen and the bone marrow may offer prognostic information.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sachpekidis C, Stein-Thoeringer CK, Kopp-Schneider A, et al. Can physiologic colonic [18F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma? Eur J Nucl Med Mol Imaging. 2023. PMID: 37452874. doi:10.1007/s00259-023-06327-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。